PCM
PBYI icon

Prelude Capital Management’s Puma Biotechnology PBYI Stock Holding History

Prelude Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-800
Closed -$53K – 2062
2014
Q2 		$53K Buy
+800
New +$56.9K 0.01% 1343

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Prelude Capital Management's PBYI Position: Q1 2026 in Review

Prelude Capital Management reduced its Puma Biotechnology (PBYI) stake by 43% in Q1 2026, selling an estimated $88.3K and leaving 18,448 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #1023.

Prelude Capital Management first reported a position in PBYI in Q1 2015 and has held it in 14 quarters since. The position peaked at $1.22M in Q4 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Prelude Capital Management held 18,448 shares of Puma Biotechnology worth $118K as of Q1 2026.
  • Prelude Capital Management sold 13,700 Puma Biotechnology shares in Q1 2026, an estimated $88.3K.
  • Puma Biotechnology made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1023 holding.
  • Prelude Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 14 quarters since.
  • Prelude Capital Management's Puma Biotechnology position peaked at $1.22M in Q4 2017.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.